Back

Recombinant measles virus equipped with BNiP3, a pro-apoptotic gene, targets β-catenin pathway in triple negative breast cancer cells

Rajala, M. S.; Kumar, A.; Yadav, K.; Upadhyay, G. S.

2026-04-18 cancer biology
10.64898/2026.04.15.718830 bioRxiv
Show abstract

Oncolytic virotherapy is an emerging cancer therapy using genetically modified viruses. We previously reported engineering of measles virus with BNiP3, a proapoptotic gene for oncolytic purposes. The recombinant virus had shown promising results in breast cancer cells with a bias towards TNBC, an invasive and an aggressive subtype. Here, we investigated the mechanistic insights of anti-tumor effects induced by the recombinant virus. Initially, TNBC and non-TNBC tumor cell lines were compared bioinformatically using the available gene expression data through protein-protein interaction network using different topological properties. Four hub genes involved in tumor development and progression were identified to be the top genes in both the data sets. Of which, CTNNB1 gene encoding {beta}-catenin was found to be the significant one; as {beta}-catenin pathway is known to be a driver of tumor cell invasion and migration, the impact of the virus on this pathway was investigated in breast tumor cells. The results had demonstrated a notable decrease in {beta}-catenin expression and its downstream targets, cyclin D1, MMP7 reducing the migration potential of TNBC cells following virus infection. These findings suggest that the recombinant measles virus could be one of the effective treatment modalities to target invasive TNBC tumors. In vivo validation of engineered virus is ongoing to explore the therapeutic application of this virus. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=126 SRC="FIGDIR/small/718830v1_ufig1.gif" ALT="Figure 1"> View larger version (57K): org.highwire.dtl.DTLVardef@121de77org.highwire.dtl.DTLVardef@9473eeorg.highwire.dtl.DTLVardef@473ec4org.highwire.dtl.DTLVardef@169e94b_HPS_FORMAT_FIGEXP M_FIG C_FIG HighlightsO_LIUse of recombinant measles virus with a pro-apoptotic gene, BNiP3 to target breast cancer cells C_LIO_LIIdentification of top regulatory genes in breast cancer development and progression C_LIO_LIReduction of {beta}-catenin expression encoded by CTNNB1 gene in TNBC cells following virus infection C_LIO_LIDownregulation of {beta}-catenin downstream targets in TNBC cells with virus infection C_LIO_LIInhibition of migratory potential of TNBC cells following infection C_LI

Matching journals

The top 18 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 1.0%
5.0%
2
Antiviral Research
49 papers in training set
Top 0.1%
5.0%
3
Frontiers in Oncology
95 papers in training set
Top 0.8%
4.4%
4
Frontiers in Genetics
197 papers in training set
Top 2%
3.7%
5
PLOS ONE
4510 papers in training set
Top 41%
3.3%
6
Scientific Reports
3102 papers in training set
Top 40%
3.2%
7
Frontiers in Pharmacology
100 papers in training set
Top 1%
3.2%
8
BMC Cancer
52 papers in training set
Top 0.8%
2.7%
9
PeerJ
261 papers in training set
Top 4%
2.4%
10
Viruses
318 papers in training set
Top 2%
2.1%
11
Journal of Translational Medicine
46 papers in training set
Top 0.5%
2.1%
12
Heliyon
146 papers in training set
Top 1.0%
2.1%
13
Frontiers in Immunology
586 papers in training set
Top 3%
2.1%
14
PLOS Pathogens
721 papers in training set
Top 5%
1.9%
15
iScience
1063 papers in training set
Top 11%
1.9%
16
International Journal of Molecular Sciences
453 papers in training set
Top 7%
1.7%
17
Computers in Biology and Medicine
120 papers in training set
Top 2%
1.7%
18
Pharmaceuticals
33 papers in training set
Top 0.7%
1.7%
50% of probability mass above
19
Cell Communication and Signaling
35 papers in training set
Top 0.5%
1.5%
20
Frontiers in Molecular Biosciences
100 papers in training set
Top 2%
1.5%
21
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 5%
1.5%
22
Molecules
37 papers in training set
Top 0.9%
1.5%
23
Disease Models & Mechanisms
119 papers in training set
Top 1%
1.4%
24
PLOS Computational Biology
1633 papers in training set
Top 19%
1.3%
25
Cancer Letters
32 papers in training set
Top 0.5%
1.0%
26
F1000Research
79 papers in training set
Top 3%
1.0%
27
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.7%
0.9%
28
Antibody Therapeutics
16 papers in training set
Top 0.4%
0.9%
29
Cell Death & Disease
126 papers in training set
Top 2%
0.9%
30
Biomedicines
66 papers in training set
Top 2%
0.8%